University of Notre Dame researchers are leveraging the International Space Station National Laboratory to enhance biosensing technology for earlier cancer detection
CAPE CANAVERAL, Fla., Sept. 3, 2024 /PRNewswire/ — The University of Notre Dame is leading a series of groundbreaking experiments onboard the International Space Station (ISS) to revolutionize early cancer detection. This research, featured in the latest issue of Upward, official magazine of the ISS National Laboratory®, demonstrates how bubbles formed in microgravity can significantly enhance biosensing technology by concentrating microscopic substances more effectively than on Earth.
The just-completed third experiment, which launched to the ISS on Northrop Grumman’s 21st Commercial Resupply Services mission to the orbiting laboratory, contracted by NASA, builds on the team’s earlier ISS National Lab-sponsored research. This most recent investigation successfully introduced laser heating to refine bubble behavior, increasing the concentration of particles collected—an essential step toward detecting early cancer biomarkers and other trace elements in blood. These advancements could dramatically improve the sensitivity of biosensors, opening the door to earlier and more accurate cancer detection.
“The technology currently available to screen for early, asymptomatic cancer before a tumor is visible during imaging is very limited to just a few cancers,” says principal investigator Tengfei Luo, associate chair in the department of aerospace and mechanical engineering at the University of Notre Dame, in the Upward article. “If cancer screening using our bubble technology in space is democratized and made inexpensive, many more cancers can be screened, and everyone can benefit. It’s something we may be able to integrate into annual exams. It sounds far-fetched, but it’s achievable.”
ISS National Lab Commercial Service Provider Space Tango worked with Luo’s team to develop specialized CubeLab hardware to automate the study of bubble formation and behavior in microgravity. The hardware includes advanced imaging systems designed to capture high-resolution data on bubble dynamics.
“We’re using the unique space environment to push the boundaries of what’s possible in biosensing,” Luo said. “Our ultimate goal is to make these powerful diagnostic tools widely accessible and affordable on Earth and to accelerate diagnostics that are only possible in space.”
For more details about the ongoing research, read the full article in Upward.
To download a high-resolution image for this release, click here.
About the International Space Station (ISS) National Laboratory:
The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Laboratory® allows researchers to leverage this multiuser facility to improve quality of life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology, and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space™ (CASIS™) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit our website.
As a 501(c)(3) nonprofit organization, CASIS accepts corporate and individual donations to help advance science in space for the benefit of humanity. For more information, visit our donations page.
Media Contact: |
Patrick O’Neill |
904-806-0035 |
|
International Space Station (ISS) National Laboratory |
Managed by the Center for the Advancement of Science in Space, Inc. (CASIS) |
6905 N. Wickham Rd., Suite 500, Melbourne, FL 32940 • 321.253.5101 • www.ISSNationalLab.org |
SOURCE International Space Station National Lab
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…
BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…
HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…
Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…
Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…